Climb Bio (CLYM) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Climb Bio (CLYM) has outperformed Wave Life Sciences (WVE) over the past year, gaining 440.6% versus a loss of 63.7%. Over five years, CLYM leads with a -33.2% price change compared with -35.8% for WVE. Climb Bio is the larger company by market cap ($539.8 million vs $504.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | WVE |
|---|---|---|
| Share price | $9.19 | $2.56 |
| Market cap | $539.80M | $504.91M |
| 1-day change | -0.97% | -5.88% |
| YTD return | +129.75% | -84.94% |
| 1-year return | +440.59% | -63.69% |
| 5-year return | -33.21% | -35.84% |
| EPS (TTM) | $-0.81 | $-1.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $42.73M |
| Revenue growth (YoY) | — | -60.55% |
| Net income (latest FY) | $-59.85M | $-204.38M |
| Operating margin | — | -504.09% |
| Net margin | — | -478.33% |
| 52-week high | $18.33 | $21.73 |
| 52-week low | $1.64 | $2.55 |
| Distance from 52-week high | -49.86% | -88.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +209.03% | +549.61% |
| Average volume | 1.38M | 3.11M |
| Shares outstanding | 58.74M | 197.23M |
| Employees | 28 | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed WVE by 504.3 percentage points over the past year.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
CLYM vs WVE FAQ
Which is bigger, Climb Bio or Wave Life Sciences?
Climb Bio (CLYM) is larger, with a market capitalization of $539.80M compared with $504.91M for Wave Life Sciences (WVE).
Which stock has performed better over the past year, CLYM or WVE?
CLYM returned +440.59% over the past 12 months, compared with -63.69% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and Wave Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.